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SSRIs for depression/heart 
failure patients? Not so fast
This study should put to rest the practice of starting SSRIs 
in depressed patients with heart failure in an attempt to 
affect CVD outcomes.  
PRACTICE CHANGER
Do not prescribe selective serotonin reuptake 
inhibitors to improve depression and reduce 
cardiovascular risk in patients with conges-
tive heart failure. 
STRENGTH OF RECOMMENDATION
B: Based on one large randomized controlled 
trial.
Angermann CE, Gelbrick G, Störk S, et al, for the MOOD-HF Study 
Investigators and Committee Members. Effect of escitalopram on 
all-cause mortality and hospitalization in patients with heart failure 
and depression. The MOOD-HF randomized clinical trial. JAMA. 
2016;315:2683-2693.1 
ILLUSTRATIVE CASE
A 60-year-old man comes to your office for 
a follow-up visit to talk about his congestive 
heart failure. He has New York Heart Associa-
tion Class III heart failure with a left ventricu-
lar ejection fraction of 30%. You notice that 
he is downcast, and after evaluation, includ-
ing a score of 17 on a self-administered 9-item 
Patient Health Questionnaire (PHQ-9), you de-
termine that he is having a concomitant major 
depressive episode. Should you start him on a 
selective serotonin reuptake inhibitor (SSRI)? 
Depression is widely recognized as an independent risk factor for both the development of cardiovascular 
disease (CVD), as well as adverse outcomes 
in patients with known CVD.2-5 Previous stud-
ies have identified poor health behaviors as 
the primary underlying mechanisms linking 
depression and the risk of CVD.2,6 Conversely, 
a recent systematic review suggests that posi-
tive constructs—mediated primarily through 
lifestyle behaviors—may have a protective ef-
fect on CVD outcomes.7 
As a result, researchers have focused 
on the treatment of depression to improve 
CVD outcomes in recent years, including in 
patients with heart failure. While some ran-
domized studies have shown that SSRIs are 
a safe and effective treatment for depression 
in patients with coronary disease, they have 
not demonstrated improvement in CVD out-
comes.8,9 However, a post hoc analysis of the 
ENRICHD (Enhancing Recovery in Coronary 
Heart Disease) trial did suggest that SSRI 
treatment may improve mortality and mor-
bidity post-myocardial infarction.10
The prevalence of depression among 
patients with heart failure ranges from 10% 
to 40%, depending on disease severity.11 De-
pression is associated with worse quality of 
life, poorer treatment adherence, and higher 
rates of rehospitalization among patients with 
heart failure, and is an independent predictor 
of mortality in this patient population.1 Until 
recently, only one randomized controlled trial 
(RCT), the SADHART-CHF (Sertraline Against 
Depression and Heart Disease in Chronic 
Heart Failure) study, looked at treatment with 
SSRIs in patients with heart failure and depres-
sion.12 In this trial, sertraline, when compared 
with placebo, did not improve depression or 
CVD outcomes over 12 weeks, but the study 
period may have been insufficiently long to 
capture the impact on long-term outcomes. 
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STUDY SUMMARY
SADHART-CHF, but better 
In the MOOD-HF (The effects of selective 
serotonin re-uptake inhibition on morbid-
ity, mortality, and mood in depressed heart 
failure patients) study, investigators sought 
to determine whether SSRI treatment for de-
pression in patients with heart failure could 
improve CVD outcomes over a longer study 
period (up to 24 months).1 Specifically, this 
RCT assessed whether treatment with escital-
opram vs placebo could reduce the increased 
morbidity and mortality risk in patients with 
comorbid chronic systolic heart failure and 
depression. 
This double-blind, placebo-controlled 
trial was conducted at 16 tertiary medical 
centers in Germany between 2009 and 2014. 
Adult patients established at heart failure 
clinics with New York Heart Association class 
II to IV heart failure and left ventricular ejec-
tion fractions <45% were screened for de-
pression using the PHQ-9. Individuals with 
PHQ-9 scores ≥12 underwent a structured 
psychiatric interview with a psychiatrist or 
psychosomatic specialist. Those who re-
ceived a diagnosis of major depression were 
invited to participate in the trial. Patients with 
recent SSRI use and/or psychotherapy were 
excluded from participation.
❚ Eligible participants were randomized 
to receive either escitalopram (10-20 mg/d) 
or placebo for up to 24 months in addition to 
standard heart failure care. The starting dose 
of 5 mg was increased to 10 to 20 mg as tol-
erated until week 12 of the study; the dose at 
12 weeks was considered the maintenance 
dose. Psychiatric and medical assessments 
were performed every 6 months during the 
study period. Depression severity was as-
sessed using the 10-item Montgomery-Åsberg 
Depression Rating Scale (MADRS). 
❚ Outcomes. The primary study outcome 
was time to a first event of the composite of 
all-cause death or hospitalization. Second-
ary outcomes included MADRS score at 
12 weeks, anxiety as assessed by the General-
ized Anxiety Disorder 7-item scale (GAD-7), 
and health-related quality of life (QoL) as as-
sessed by the Kansas City Cardiomyopathy 
Questionnaire (KCCQ). The sample size was 
calculated to achieve 80% power for the pri-
mary outcome. Baseline characteristics be-
tween the intervention and placebo groups 
were balanced after randomization, and the 
modified intention-to-treat study population 
included participants who took at least one 
dose of the study medication.1 
❚ Results. Ultimately, 372 participants 
were included in the analysis (185 in the es-
citalopram group and 187 in the placebo 
group). A primary endpoint event occurred 
in 116 participants (63%) in the escitalo-
pram group and in 119 participants (64%) in 
the placebo group (hazard ratio [HR]=0.99; 
95% confidence interval [CI], 0.76 to 1.27]; 
P=.92).1 No differences were found between 
treatment groups for the primary endpoints 
in either adjusted or unadjusted analyses. 
The mean (SD) MADRS score changed 
from 20.2 (8.6) at baseline to 11.2 (8.1) at 
12 weeks with escitalopram and from 
21.4 (8.8) to 12.5 (7.6) in the placebo group 
(between-group difference = -0.9; 95% CI, 
-2.6 to 0.7; P =.26).10 Overall, participants in 
the 2 treatment groups had comparable daily 
doses of study medications, as well as mean 
treatment duration (18 months), and both 
groups demonstrated partial remission of 
depression symptoms over the study period, 
as well as improved health status and QoL as 
measured by KCCQ. 
Interestingly, QoL as assessed by the 
KCCQ symptom score was significantly im-
proved in the placebo group at 12 months.1 
There were no between-group differences in 
adverse events or safety measures.1 The trial 
was discontinued prematurely on February 
28, 2014, based on futility after a recommen-
dation from the data and safety monitoring 
committee. 
WHAT’S NEW
Longer study period/different SSRI  
doesn’t change earlier finding
The MOOD-HF trial directly addresses the 
major criticism of the SADHART-CHF trial 
by looking at SSRI treatment of patients with 
heart failure and depression over a much 
longer study duration (up to 24 months vs 
12 weeks). Also, in contrast to SADHART-
CHF, this trial studied escitalopram, rather 
than sertraline, because some evidence indi-
Using SSRIs  
for depression 
treatment  
to affect chronic 
disease  
outcomes 
that are likely 
lifestyle-related 
may not be  
cost-effective  
or patient- 
centered.
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Although there 
are other SSRIs 
besides  
escitalopram 
and sertraline,  
it is likely that 
this is a class 
effect. 
cates that escitalopram is superior at treating 
primary depression.13 Despite these differ-
ences, the results of MOOD-HF are consis-
tent with the findings of SADHART-CHF: 
treating patients with both heart failure and 
depression with an SSRI did not improve the 
elevated morbidity and mortality risk seen 
with these comorbid conditions. 
Also consistent with SADHART-CHF 
findings, participants in both groups in the 
MOOD-HF trial had partial remission of de-
pressive symptoms over the study period, 
with no significant difference between those 
treated with escitalopram vs placebo. Given 
that this high-quality trial, with a much lon-
ger treatment period and a possibly more 
effective SSRI, replicated the findings of 
SADHART-CHF, the results of MOOD-HF 
should put to rest the practice of initiating 
SSRI treatment in depressed patients with 
heart failure in an attempt to affect CVD 
outcomes. 
CAVEATS
There are other SSRI fish in the sea
There are other SSRIs, besides escitalopram 
and sertraline, available for use. However, it 
is likely that this is a class effect. 
Additionally, none of the patients in this 
trial had severe depression, as their PHQ-9 
scores were all below 19. Therefore, it re-
mains to be determined if treating patients 
with severe depression has an impact on car-
diovascular outcomes. 
Lastly, and most importantly, this study 
only looked at screening patients for depres-
sion and initiating SSRIs in the setting of heart 
failure. The trial did not include patients al-
ready taking SSRIs for pre-existing depres-
sion. Thus, the results do not imply evidence 
for discontinuing SSRIs in patients with heart 
failure.
Treating comorbid depression and CVD 
to improve the elevated risk for adverse clini-
cal outcomes remains nuanced and elusive. 
In fact, the same can be said of non-CVD 
chronic conditions—such as diabetes—
based on recent systematic reviews.13 The 
summation of these studies suggests that a 
traditional screen-and-treat approach utiliz-
ing SSRIs for depression treatment to affect 
chronic disease outcomes (that are likely 
lifestyle-related) may not be cost-effective or 
patient-centered. 
The publication of a recent study showing 
that cognitive behavioral therapy did improve 
depression—but not heart failure—among 
patients with both conditions14 reaffirms 
that teasing out the impact of depression on 
lifestyle behaviors and chronic disease out-
comes among multimorbid patients is more 
complex than previously thought. Neverthe-
less, this is an area of research that should 
continue to be explored, given the obvious 
increased risk for poorer chronic disease out-
comes in the presence of depression. 
CHALLENGES TO IMPLEMENTATION
Changing the tide can be difficult
As with any behavior change among provid-
ers, we expect that it will be a challenge to 
convince providers to stop screening for de-
pression and initiating treatment with an SSRI 
to affect CV outcomes in patients with heart 
failure. This is especially so given the body 
of evidence for depression as a risk factor 
for increased morbidity and mortality in this 
population.                   JFP 
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